Launched in 2023, the MyMelanoma study is the most ambitious melanoma research project undertaken in the UK. Led by the University of Oxford and managed through Oxford Cancer, it aims to recruit 20,000 UK melanoma patients in order to carry out the largest study of melanoma ever performed, to improve understanding of melanoma skin cancer and its treatment.
MyMelanoma has been selected as one of three cancer-focussed studies (alongside a fourth seeking to improve the care of young children needing complex surgery) to pilot the new NHS DigiTrials recruitment service, which is managed by NHS England. The service aims to identify NHS patients who might be suitable for a certain trial and contacts them to see if they would like to take part.
Commenting on the news, Professor Mark Middleton, Chief Investigator of MyMelanoma, Head of the Department of Oncology and Co-Director of Oxford Cancer, said:
“Being chosen as one of 4 studies to pilot the NHS’s DigiTrials recruitment service is an amazing opportunity for MyMelanoma and the patients with whom we work. Our partnership will let us offer patients all around the country both the chance to take part in research into melanoma, and to have a say in how that research is done. It will help make MyMelanoma the largest ever melanoma study and let us answer research questions we simply couldn’t tackle before, with the goal of providing a more individualised approach to patient care”.
Read the full story on the Oxford Cancer website.
more recommended stories
Air Pollution Hurts Brain Health in Just 4 HoursAir Pollution Blurs the Mind, Impairs.
New therapies developed by Oxford experts offer online support for anxiety and post-traumatic stress disordersUrgent treatment solutions are needed for.
three key pillars to tackle antimicrobial resistance effectively — University of Oxford, Medical Sciences DivisionThe High-Level Meeting on antimicrobial resistance.
Oxford Vaccine Group marks 30 years battling ‘deadly six’ diseases with major art installation — University of Oxford, Medical Sciences DivisionThe installation was commissioned to mark.
Professor Ahmed Awarded Funding To Create World’s First Ovarian Cancer Prevention Vaccine — University of Oxford, Medical Sciences DivisionScientists at the University of Oxford,.
New research network unites Oxford University’s global fight against antimicrobial resistance — University of Oxford, Medical Sciences DivisionAntimicrobial resistance (AMR) threatens the foundation.
Typhoid vaccine trial confirms sustained protection for older children — University of Oxford, Medical Sciences DivisionThe TyVOID study, published in the Lancet, measured the.
Study Publishes New Insights on Goblet Cell Differentiation in Colorectal Cancer — University of Oxford, Medical Sciences DivisionThe research addresses the long-recognized poor.
Four Oxford researchers win prestigious Philip Leverhulme Prizes — University of Oxford, Medical Sciences DivisionOnly 30 prizes are awarded throughout.
Kavli Oxford’s Nick Gatford Wins Image of Distinction Award in Nikon Small World Competition — University of Oxford, Medical Sciences DivisionThe Nikon Small World competition, often.
Leave a Comment